InspireMD Welcomes New Board Member Raymond W. Cohen
InspireMD, Inc. (Nasdaq: NSPR), a prominent developer of innovative medical technologies, is excited to announce the addition of Raymond W. Cohen to its Board of Directors. This strategic appointment is set to infuse the company with over four decades of Cohen’s extensive leadership experience in the medical technology sector.
Raymond W. Cohen: A Proven Leader
Raymond W. Cohen is recognized for his remarkable record of scaling operations and creating value for shareholders through strategic growth and successful exits. His leadership capabilities were showcased during his tenure as the CEO and co-founder of Axonics, Inc., navigating the company through a successful public offering and culminating in a substantial acquisition by Boston Scientific.
His leadership was pivotal at Axonics, where the company garnered accolades, including being recognized as the fastest-growing company in the Americas by notable organizations in 2021. This impressive track record exemplifies his ability to drive transformative growth while ensuring strong operational performance.
Expertise to Enhance InspireMD's Vision
“We are thrilled to welcome Ray to InspireMD’s Board of Directors,” expressed Marvin Slosman, CEO of InspireMD. “His insights and vast experience will be invaluable to our strategic direction. With the recent approval of our CGuard Prime carotid stent system, we are entering an exciting phase. We are eager to leverage Cohen’s expertise to further our mission of combating stroke and bringing innovative solutions to market.”
In addition to his leadership role at InspireMD, Cohen previously served as Chairman at SoniVie Ltd., a company focused on hypertension treatment until its acquisition, and he remains an independent director at several other medical firms. His broad experience across various roles in different organizations positions him as a vital asset in shaping InspireMD's growth strategies and enhancing its operational effectiveness.
A Commitment to Innovation and Patient Care
Cohen emphasizes the importance of pioneering technology in healthcare. “The CGuard Prime stent system is a remarkable innovation that sets new standards in carotid stenting,” he stated. “InspireMD's commitment to maintaining an industry-leading position through entrepreneurial agility and clinical excellence highlights its potential for substantial market impact.”
InspireMD's state-of-the-art MicroNet™ mesh technology aims to redefine the carotid stenting landscape by ensuring both immediate and long-term safety outcomes for patients. As the company continues to work towards its commercial launch, the integration of Cohen into the team is anticipated to streamline operations and maximize market penetration.
About InspireMD
InspireMD is dedicated to revolutionizing carotid artery treatment through advanced technology and patient-centered care. Their proprietary CGuard Prime system is a testament to this dedication, promising improved patient outcomes and continued innovation in the field of medical technology. The company’s shares are traded on Nasdaq under the ticker NSPR, reflecting its ongoing commitment to its stakeholders.
For further insights into InspireMD's ongoing projects and future directions, please visit www.inspiremd.com.
Frequently Asked Questions
Who is Raymond W. Cohen?
Raymond W. Cohen is a seasoned leader in medical technology with extensive experience in scaling businesses and creating shareholder value.
What is InspireMD known for?
InspireMD is known for developing innovative medical solutions, particularly the CGuard Prime carotid stent system aimed at preventing strokes.
How will Cohen’s appointment impact InspireMD?
Cohen’s experience is expected to enhance InspireMD's strategic direction and operational efficiency as they prepare for product launches.
When was Cohen appointed to the board?
While the announcement was made recently, specific dates of the appointment were not disclosed.
What technology does InspireMD utilize?
InspireMD employs proprietary MicroNet™ mesh technology in its products to ensure high safety and efficacy in carotid stenting.
